会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHOD AND KIT FOR PATHOLOGIC GRADING OF BREAST NEOPLASM
    • 乳腺癌的病理学分级方法和工具包
    • WO2016118078A1
    • 2016-07-28
    • PCT/SG2015/050368
    • 2015-10-04
    • TEH, Bin TeanTAN, Boon Ooi PatrickTAN, Puay Hoon
    • TEH, Bin TeanTAN, Boon Ooi PatrickTAN, Puay HoonTAN, JingONG, Choon KiatLIM, Weng KhongNG, Chuan Young Cedric
    • C12Q1/68C12N15/09
    • C12Q1/6886C12Q2600/112C12Q2600/156
    • The present disclosure is a method comprising the steps of performing one or more nucleic-acid based assays to identify mutations present in the breast tissue acquired from the subject corresponding to a first test module and a second test module associated with detection of at least one predetermined mutation of one or more genes, wherein each test module is configured to provide a positive outcome corresponding to at least one predetermined mutation detected in the tissue or a negative outcome corresponding to absence of detectable predetermined mutation in the sample; and identifying the type of neoplasm of the breast tissue based upon the provided outcome of the both test modules. Preferably, the first test module is associated with detection of mutation in MED12 gene and/or RARA gene, while the second test module is associated with detection of mutation in FLNA gene, SETD2 gene and/or MLL2 gene.
    • 本公开是一种方法,其包括以下步骤:执行一个或多个基于核酸的测定,以鉴定从与第一测试模块相对应的从受试者获得的乳腺组织中存在的突变,以及与检测至少一个预定的 一个或多个基因的突变,其中每个测试模块被配置为提供对应于组织中检测到的至少一个预定突变的阳性结果或对应于样品中不可检测到的预定突变的否定结果; 并且基于两个测试模块的提供的结果来识别乳腺组织的肿瘤的类型。 优选地,第一测试模块与检测MED12基因和/或RARA基因中的突变相关,而第二测试模块与FLNA基因,SETD2基因和/或MLL2基因中的突变的检测相关。